Work

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Year: 2009

Type: article

Source: Oncogene

DOI: 10.1038/onc.2009.403

Authors: V Ramakrishnan, M Timm, J L Haug, T K Kimlinger, L E Wellik, T E Witzig, S V Rajkumar, A A Adjei, S Kumar

Institutions: Mayo Clinic, Roswell Park Comprehensive Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Mayo Clinic, Mayo Foundation for Medical Education and Research, National Institutes of Health, National Cancer Institute

Awards: G2660289629, G630064964, Signal transduction inhibitor therapy for Lymphoma, Cancer Center Support Grant

OpenAlex ID: W2073363483

FWCI: 5.541

Cites: 44

Cited by: 98

Related to: 10